血液透析联合罗沙司他治疗慢性肾衰竭合并严重贫血的疗效及不良反应发生率分析  

Efficacy and Incidence of Adverse Reactions of Hemodialysis Combined with Roxallistat in the Treatment of Chronic Renal Failure Complicated with Severe Anemia

作　　者：花侠玲 HUA Xialing(Department of Nephrology,Pizhou People's Hospital,Pizhou,Jiangsu Province,221300 China)

机构地区：[1]江苏省邳州市人民医院肾内科,江苏邳州221300

出　　处：《中外医疗》2024年第15期60-63,共4页China & Foreign Medical Treatment

摘　　要：目的探讨血液透析联合罗沙司他治疗慢性肾衰竭合并严重贫血的疗效及不良反应发生率情况。方法随机选取2022年1月—2023年10月江苏省邳州市人民医院收治的70例慢性肾衰竭合并严重贫血患者为研究对象,使用硬币投掷法分为对照组和研究组,各35例。两组均采取连续性血液透析治疗,在此基础上,对照组使用重组人促红素注射液治疗,研究组则是使用罗沙司他胶囊治疗,分析比较两组的治疗效果。结果治疗前,两组的红细胞压积、血红蛋白浓度比较,差异无统计学意义(P均>0.05);治疗后,两组的红细胞压积、血红蛋白浓度均改善,且研究组的红细胞压积、血红蛋白浓度均高于对照组,差异有统计学意义(P均<0.05)。研究组的不良反应发生率(0)低于对照组(17.14%),差异有统计学意义(χ^(2)=4.557,P=0.033)。研究组的治疗总有效率(91.43%)高于对照组(71.43%),差异有统计学意义(χ^(2)=4.629,P=0.031)。结论慢性肾衰竭患者积极使用罗沙司他胶囊进行持续性血液透析治疗,安全性和有效性更高,可减轻患者的贫血程度,并有效减少不良反应的发生。Objective To investigate the efficacy and incidence of adverse reactions of hemodialysis combined with Roxallistat in the treatment of chronic renal failure complicated with severe anemia.Methods Seventy patients with chronic renal failure complicated with severe anemia admitted to Pizhou People's Hospital of Jiangsu Province from January 2022 to October 2023 were randomly selected as the study subjects.They were divided into control group and study group by coin tossing method,with thirty-five cases in each group.Both groups were treated with continuous he⁃modialysis.On this basis,the control group was treated with recombinant human erythropoietin injection.The study group was treated with Rosallistat capsules.The therapeutic effects of the two groups were analyzed and compared.Results Before treatment,there was no statistically significant difference in hematocrit and hemoglobin concentration between the two groups(both P>0.05);after treatment,the hematocrit and hemoglobin concentrations of both groups were improved,and the hematocrit and hemoglobin concentrations of the study group were higher than those of the control group,the differences were statistically significant(both P<0.05).The incidence of adverse reactions in study group(0)was lower than that in control group(17.14%),and the difference was statistically significant(χ^(2)=4.557 P=0.033).The total effective rate of treatment in the study group(91.43%)was higher than that of the control group(71.43%),the difference was statistically significant(χ^(2)=4.629,P=0.031).Conclusion Patients with chronic renal failure actively use Rosallistat capsule for continuous hemodialysis treatment, which has higher safety and effectiveness, can reduce the degree of anemia in patients, and effectively reduce the occurrence of adverse reactions.

关 键 词：血液透析 罗沙司他 慢性肾衰竭 严重贫血 疗效 不良反应 安全性 

分 类 号：R692.5[医药卫生—泌尿科学] R556[医药卫生—外科学]